Clinical Trial Update: A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial comparing TQB2102 to the combination of docetaxel with trastuzumab and pertuzumab for HER2-positive recurrent or metastatic bre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pertuzumab (pertuzumab)
• TQB2102
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING